Fig. 4From: Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomasEffect of trabectedin (Et-743) and rucaparib combination on cell cycle progression in four STS cell lines: IB111, IB115, IB136, and 93T449. a Cell-cycle profile after 48 h of treatment with trabectedin and/or rucaparib analyzed by PI incorporation and flow cytometry in the IB111 cell line. b Cell-cycle distribution was calculated from the flow cytogram.Back to article page